WO1987005330A1
(en)
|
1986-03-07 |
1987-09-11 |
Michel Louis Eugene Bergh |
Method for enhancing glycoprotein stability
|
US5273876A
(en)
|
1987-06-26 |
1993-12-28 |
Syntro Corporation |
Recombinant human cytomegalovirus containing foreign gene
|
WO1990009441A1
(en)
|
1989-02-01 |
1990-08-23 |
The General Hospital Corporation |
Herpes simplex virus type i expression vector
|
US5614396A
(en)
|
1990-06-14 |
1997-03-25 |
Baylor College Of Medicine |
Methods for the genetic modification of endogenous genes in animal cells by homologous recombination
|
WO1992003917A1
(en)
|
1990-08-29 |
1992-03-19 |
Genpharm International |
Homologous recombination in mammalian cells
|
GB9105383D0
(en)
|
1991-03-14 |
1991-05-01 |
Immunology Ltd |
An immunotherapeutic for cervical cancer
|
AU3972893A
(en)
|
1992-04-03 |
1993-11-08 |
Baylor College Of Medicine |
Gene therapy using the intestine
|
US5674703A
(en)
|
1992-12-02 |
1997-10-07 |
Woo; Savio L. C. |
Episomal vector systems and related methods
|
AU684524B2
(en)
|
1993-06-14 |
1997-12-18 |
Tet Systems Holding Gmbh & Co. Kg |
Tight control of gene expression in eucaryotic cells by tetracycline-responsive promoters
|
EP0728202A4
(en)
|
1993-11-12 |
1997-04-23 |
Univ Case Western Reserve |
EPISOMIC EXPRESSION VECTOR FOR HUMAN GENE THERAPY
|
US5731172A
(en)
|
1994-03-09 |
1998-03-24 |
Sumitomo Pharmaceuticals Company, Ltd. |
Recombinant adenovirus and process for producing the same
|
US5604090A
(en)
|
1994-06-06 |
1997-02-18 |
Fred Hutchinson Cancer Research Center |
Method for increasing transduction of cells by adeno-associated virus vectors
|
US5693508A
(en)
|
1994-11-08 |
1997-12-02 |
Chang; Lung-Ji |
Retroviral expression vectors containing MoMLV/CMV-IE/HIV-TAR chimeric long terminal repeats
|
JP3770333B2
(ja)
|
1995-03-15 |
2006-04-26 |
大日本住友製薬株式会社 |
組換えdnaウイルスおよびその製造方法
|
US6110456A
(en)
|
1995-06-07 |
2000-08-29 |
Yale University |
Oral delivery or adeno-associated viral vectors
|
US5695977A
(en)
|
1995-08-31 |
1997-12-09 |
Genetic Information Research Institute |
Site directed recombination
|
US6013516A
(en)
|
1995-10-06 |
2000-01-11 |
The Salk Institute For Biological Studies |
Vector and method of use for nucleic acid delivery to non-dividing cells
|
DE69708318T3
(de)
|
1996-08-27 |
2006-11-16 |
Novartis Vaccines and Diagnostics, Inc., Emeryville |
Neisseria meningitidis serogruppe b glykokonjugate und verfahren zu deren verwendung
|
US20020042367A1
(en)
|
1997-11-25 |
2002-04-11 |
Genentech, Inc. |
Fibroblast growth factor-19 (FGF-19) nucleic acids and polypeptides and methods of use for the treatment of obesity and related disorders
|
US20060246540A1
(en)
|
1997-08-26 |
2006-11-02 |
Ashkenazi Avi J |
Secreted and transmembrane polypeptides and nucleic acids encoding the same
|
US20020012961A1
(en)
|
1999-04-15 |
2002-01-31 |
Genentech, Inc. |
Fibroblast growth factor- 19
|
US20030113718A1
(en)
|
1997-09-17 |
2003-06-19 |
Genentech, Inc. |
Secreted and transmembrane polypeptides and nucleic acids encoding the same
|
US20030077654A1
(en)
|
1997-09-17 |
2003-04-24 |
Genentech, Inc. |
Secreted and transmembrane polypeptides and nucleic acids encoding the same
|
CA2303834A1
(en)
|
1997-09-17 |
1999-03-25 |
Genentech, Inc. |
Secreted and transmembrane polypeptides and nucleic acids encoding the same
|
US6806352B2
(en)
|
1997-09-17 |
2004-10-19 |
Genentech, Inc. |
Secreted and transmembrane polypeptides and nucleic acids encoding the same
|
US20050026832A1
(en)
|
1997-11-25 |
2005-02-03 |
Genentech, Inc. |
Fibroblast growth factor-19 (FGF-19) nucleic acids and polypeptides and methods of use for the treatment of obesity and related disorders
|
US20040126852A1
(en)
|
1997-11-25 |
2004-07-01 |
Genentech, Inc. |
Fibroblast growth factor-19 (FGF-19) nucleic acids and polypeptides and methods of use for the treatment of obesity
|
US20020155543A1
(en)
|
1997-11-25 |
2002-10-24 |
Genentech, Inc. |
Fibroblast growth factor-19 (FGF-19) nucleic acids and polypeptides and methods of use for the treatment of obesity and related disorders
|
AU3924300A
(en)
|
1999-04-02 |
2000-10-23 |
Millennium Pharmaceuticals, Inc. |
Fibroblast growth factor-20
|
US7390879B2
(en)
|
1999-06-15 |
2008-06-24 |
Genentech, Inc. |
Secreted and transmembrane polypeptides and nucleic acids encoding the same
|
US7129072B1
(en)
|
1999-08-30 |
2006-10-31 |
New York University |
Crystal of fibroblast growth factor receptor 1 in complex with fibroblast growth factor
|
US7459540B1
(en)
|
1999-09-07 |
2008-12-02 |
Amgen Inc. |
Fibroblast growth factor-like polypeptides
|
WO2001018209A1
(en)
|
1999-09-10 |
2001-03-15 |
Curagen Corporation |
Fibroblast growth factor polypeptide and nucleic acids encoding same
|
US6797695B1
(en)
|
1999-10-22 |
2004-09-28 |
Kyoto University |
Human FGF-20 gene and gene expression products
|
US6716626B1
(en)
|
1999-11-18 |
2004-04-06 |
Chiron Corporation |
Human FGF-21 nucleic acids
|
ATE446365T1
(de)
|
1999-11-18 |
2009-11-15 |
Novartis Vaccines & Diagnostic |
Menschliches fgf-21 gen und genexpressionsprodukte
|
DE10160151A1
(de)
|
2001-01-09 |
2003-06-26 |
Ribopharma Ag |
Verfahren zur Hemmung der Expression eines vorgegebenen Zielgens
|
WO2001049740A1
(en)
|
2000-01-05 |
2001-07-12 |
Zymogenetics, Inc. |
Novel fgf homolog zfgf12
|
US20020081663A1
(en)
|
2000-01-05 |
2002-06-27 |
Conklin Darrell C. |
Novel FGF homolog ZFGF11
|
AU2631001A
(en)
|
2000-01-05 |
2001-07-16 |
Zymogenetics Inc. |
Novel fgf homolog zfgf11
|
US20010044525A1
(en)
|
2000-01-05 |
2001-11-22 |
Conklin Darrell C. |
Novel FGF Homolog zFGF12
|
EP1257645A2
(en)
|
2000-02-15 |
2002-11-20 |
Amgen Inc. |
Fibroblast growth factor-23 molecules and uses thereof
|
US20060160181A1
(en)
|
2000-02-15 |
2006-07-20 |
Amgen Inc. |
Fibroblast Growth Factor-23 molecules and uses thereof
|
US20030211576A1
(en)
|
2000-02-22 |
2003-11-13 |
Genentech, Inc. |
Secreted and transmembrane polypeptides and nucleic acids encoding the same
|
US20020082205A1
(en)
|
2000-03-08 |
2002-06-27 |
Nobuyuki Itoh |
Human FGF-23 gene and gene expression products
|
WO2001066596A2
(en)
|
2000-03-08 |
2001-09-13 |
Chiron Corporation |
Human fgf-23 gene and gene expression products
|
WO2001072957A2
(en)
|
2000-03-31 |
2001-10-04 |
Nobuyuki Itoh |
Fibroblast growth factor-like molecules and uses thereof
|
US20030065140A1
(en)
|
2000-04-03 |
2003-04-03 |
Vernet Corine A.M. |
Novel proteins and nucleic acids encoding same
|
JP2002112772A
(ja)
|
2000-07-10 |
2002-04-16 |
Takeda Chem Ind Ltd |
新規ポリペプチドおよびそのdna
|
AU7332301A
(en)
|
2000-07-19 |
2002-02-05 |
Advanced Res & Tech Inst |
Novel fibroblast growth factor (FGF23) and methods for use
|
JP2004516013A
(ja)
|
2000-07-20 |
2004-06-03 |
ジェネンテック・インコーポレーテッド |
血管形成に関連する障害を診断及び治療するための組成物と方法
|
US6812339B1
(en)
|
2000-09-08 |
2004-11-02 |
Applera Corporation |
Polymorphisms in known genes associated with human disease, methods of detection and uses thereof
|
US20070037165A1
(en)
|
2000-09-08 |
2007-02-15 |
Applera Corporation |
Polymorphisms in known genes associated with human disease, methods of detection and uses thereof
|
US7265210B2
(en)
|
2000-09-15 |
2007-09-04 |
Genentech, Inc. |
Anti-PRO9821 antibodies
|
IL139380A0
(en)
|
2000-10-31 |
2001-11-25 |
Prochon Biotech Ltd |
Active variants of fibroblast growth factor
|
US20030045489A1
(en)
|
2000-11-22 |
2003-03-06 |
Murphy John E. |
Methods for modulating angiogenesis
|
US20020151496A1
(en)
|
2000-12-08 |
2002-10-17 |
Bringmann Peter W. |
Novel fibroblast growth factors
|
DE10100588A1
(de)
|
2001-01-09 |
2002-07-18 |
Ribopharma Ag |
Verfahren zur Hemmung der Expression eines Zielgens
|
DE10100587C1
(de)
|
2001-01-09 |
2002-11-21 |
Ribopharma Ag |
Verfahren zur Hemmung der Expression eines Zielgens
|
US7250495B2
(en)
|
2001-06-20 |
2007-07-31 |
Genentech, Inc. |
PRO20044 polypeptides
|
AU2003225903A1
(en)
|
2002-03-21 |
2003-10-08 |
Curagen Corporation |
Methods of using farnesoid x receptor (fxr) agonists
|
US6987121B2
(en)
|
2002-04-25 |
2006-01-17 |
Smithkline Beecham Corporation |
Compositions and methods for hepatoprotection and treatment of cholestasis
|
AU2003243400B2
(en)
|
2002-06-07 |
2009-10-29 |
Genentech, Inc. |
Compositions and methods for the diagnosis and treatment of tumor
|
EP2366718A3
(en)
|
2002-06-28 |
2012-05-02 |
Domantis Limited |
Ligand
|
AU2003268116A1
(en)
|
2002-09-18 |
2004-04-08 |
Eli Lilly And Company |
Method for reducing morbidity and mortality in critically ill patients
|
WO2004063355A2
(en)
|
2003-01-10 |
2004-07-29 |
Protein Design Labs, Inc. |
Novel methods of diagnosis of metastatic cancer, compositions and methods of screening for modulators of matastatic cancer
|
WO2004110472A2
(en)
|
2003-06-12 |
2004-12-23 |
Eli Lilly And Company |
Fusion proteins
|
PL1648998T3
(pl)
|
2003-07-18 |
2015-03-31 |
Amgen Inc |
Specyficzne czynniki wiążące czynnik wzrostu hepatocytów
|
BRPI0416683A
(pt)
|
2003-12-10 |
2007-01-30 |
Lilly Co Eli |
muteìna de fator de crescimento de fibroblasto de humano 21 (fgf-21), ou um seu peptìdeo biologicamente ativo, polinucleotìdeo, vetor de expressão, célula hospedeira, processo para produzir um polipeptìdeo, composição farmacêutica, método para tratar um paciente, e, uso da muteìna fgf-21
|
WO2005092928A1
(en)
|
2004-03-11 |
2005-10-06 |
Fresenius Kabi Deutschland Gmbh |
Conjugates of hydroxyalkyl starch and a protein, prepared by reductive amination
|
WO2005113606A2
(en)
|
2004-05-13 |
2005-12-01 |
Eli Lilly And Company |
Fgf-21 fusion proteins
|
KR20120133403A
(ko)
|
2004-06-01 |
2012-12-10 |
도만티스 리미티드 |
증강된 혈청 반감기를 가지는 이특이성 융합 항체
|
JP2006016323A
(ja)
|
2004-06-30 |
2006-01-19 |
Hiroshima Industrial Promotion Organization |
生理活性バイオマテリアル
|
EP1789443A1
(en)
|
2004-09-02 |
2007-05-30 |
Eli Lilly And Company |
Muteins of fibroblast growth factor 21
|
EP2161281A1
(en)
|
2004-09-02 |
2010-03-10 |
Eli Lilly & Company |
Muteins of fibroblast growth factor 21
|
KR20070084069A
(ko)
|
2004-10-08 |
2007-08-24 |
도만티스 리미티드 |
Tnfr1에 대한 단일 도메인 항체 및 이의 사용 방법
|
WO2006049854A2
(en)
|
2004-10-29 |
2006-05-11 |
Genentech, Inc. |
Disruptions of genes encoding secreted proteins, compositions and methods relating thereto
|
NZ554895A
(en)
|
2004-11-03 |
2009-06-26 |
Almac Diagnostics Ltd |
Transcriptome microarray technology and methods of using the same
|
US7655627B2
(en)
|
2004-12-14 |
2010-02-02 |
Eli Lilly And Company |
Muteins of fibroblast growth factor 21
|
US20060275794A1
(en)
|
2005-03-07 |
2006-12-07 |
Invitrogen Corporation |
Collections of matched biological reagents and methods for identifying matched reagents
|
AR052741A1
(es)
|
2005-04-08 |
2007-03-28 |
Noxxon Pharma Ag |
Acidos nucleicos de union a ghrelin
|
EP2083081A1
(en)
|
2005-07-22 |
2009-07-29 |
Five Prime Therapeutics, Inc. |
Compositions and methods of treating disease with FGFR fusion proteins
|
US20090081658A1
(en)
|
2005-08-24 |
2009-03-26 |
Abdelmajid Belouchi |
Genemap of the human genes associated with crohn's disease
|
CA2637216A1
(en)
|
2006-02-10 |
2007-08-16 |
Dermagen Ab |
Novel antimicrobial peptides and use thereof
|
WO2007130673A2
(en)
|
2006-05-05 |
2007-11-15 |
Beth Israel Deaconess Medical Center |
Methods for the diagnosis and treatment of female infertility using molecular markers
|
US8168169B2
(en)
|
2006-08-09 |
2012-05-01 |
Mclean Hospital Corporation |
Methods and compositions for the treatment of medical disorders
|
EP2069768A4
(en)
|
2006-09-01 |
2010-01-20 |
American Type Culture Collecti |
COMPOSITIONS AND METHODS FOR DIAGNOSIS AND TREATMENT OF TYPE-2 DIABETES
|
EP2094733A1
(en)
|
2006-11-03 |
2009-09-02 |
U3 Pharma GmbH |
Fgfr4 antibodies
|
EP2457996B1
(en)
|
2007-01-03 |
2016-08-31 |
NeoStem Oncology, LLC |
Stem cell growth media and methods of making and using same
|
EP2068909B1
(en)
|
2007-03-30 |
2012-04-25 |
Ambrx, Inc. |
Modified fgf-21 polypeptides and their uses
|
CN101663046B
(zh)
*
|
2007-03-30 |
2017-07-28 |
Ambrx公司 |
经修饰fgf‑21多肽和其用途
|
AU2008275559B2
(en)
|
2007-04-02 |
2014-04-10 |
Genentech, Inc. |
Klotho-beta for use in treating cancer, liver disorders, gallstones, wasting syndrome and obesity-related diseases
|
EP2036539A1
(en)
|
2007-09-11 |
2009-03-18 |
Novo Nordisk A/S |
Stable formulations of amylin and its analogues
|
US20120142546A1
(en)
|
2007-12-10 |
2012-06-07 |
The Johns Hopkins University |
Hypomethylated genes in cancer
|
EP2080812A1
(en)
|
2008-01-18 |
2009-07-22 |
Transmedi SA |
Compositions and methods of detecting post-stop peptides
|
US8420088B2
(en)
|
2008-01-28 |
2013-04-16 |
Novartis Ag |
Methods and compositions using FGF23 fusion polypeptides
|
TW200936156A
(en)
|
2008-01-28 |
2009-09-01 |
Novartis Ag |
Methods and compositions using Klotho-FGF fusion polypeptides
|
US20090226459A1
(en)
|
2008-01-29 |
2009-09-10 |
Cold Spring Harbor Laboratory |
Role of fgf-19 in cancer diagnosis and treatment
|
NZ579566A
(en)
|
2008-03-19 |
2013-01-25 |
Ambrx Inc |
Modified fgf-21 polypeptides and their uses
|
US20110015345A1
(en)
|
2008-03-19 |
2011-01-20 |
Ambrx, Inc. |
Modified FGF-23 Polypeptides and Their Uses
|
AU2009226246A1
(en)
|
2008-03-21 |
2009-09-24 |
Podiceps B.V. |
Diagnostic of pre-symptomatic metabolic syndrome
|
CN101591653B
(zh)
|
2008-05-27 |
2013-07-31 |
中国人民解放军军事医学科学院野战输血研究所 |
低表达cyp7a1的肝细胞及其构建方法
|
JOP20190083A1
(ar)
|
2008-06-04 |
2017-06-16 |
Amgen Inc |
بولي ببتيدات اندماجية طافرة لـfgf21 واستخداماتها
|
US8363365B2
(en)
|
2008-06-17 |
2013-01-29 |
Semiconductor Energy Laboratory Co., Ltd. |
Semiconductor device
|
JP2011525241A
(ja)
|
2008-06-18 |
2011-09-15 |
アボット・ラボラトリーズ |
PlGF−1コンパニオン診断方法および製品
|
FR2933702A1
(fr)
|
2008-07-08 |
2010-01-15 |
Sanofi Aventis |
Antagonistes specifiques du recepteur fgf-r4
|
WO2010006214A1
(en)
|
2008-07-09 |
2010-01-14 |
Ambrx, Inc. |
Fgf-21 neutralizing antibodies and their uses
|
WO2010017198A2
(en)
|
2008-08-04 |
2010-02-11 |
Five Prime Therapeutics, Inc. |
Fgfr extracellular domain acidic region muteins
|
EA201990619A1
(ru)
|
2008-10-10 |
2019-07-31 |
Амген Инк. |
Fgf21 мутанты и их применение
|
WO2010065439A1
(en)
|
2008-12-05 |
2010-06-10 |
Eli Lilly And Company |
Variants of fibroblast growth factor 21
|
EP2385826A4
(en)
|
2009-01-09 |
2012-04-04 |
Mayo Foundation |
METHODS AND MATERIALS FOR ADMINISTERING BILIARY ACIDS
|
US20120035105A1
(en)
|
2009-01-09 |
2012-02-09 |
Sdg, Inc. |
Insulin Therapies for the Treatment of Diabetes, Diabetes Related Ailments, and/or Diseases or Conditions Other Than Diabetes or Diabetes Related Ailments
|
US20100274362A1
(en)
|
2009-01-15 |
2010-10-28 |
Avner Yayon |
Cartilage particle tissue mixtures optionally combined with a cancellous construct
|
WO2010091122A1
(en)
|
2009-02-03 |
2010-08-12 |
Amunix, Inc. |
Extended recombinant polypeptides and compositions comprising same
|
US8188040B2
(en)
|
2009-05-05 |
2012-05-29 |
Amgen Inc. |
FGF21 mutants and uses thereof
|
AU2010246038A1
(en)
|
2009-05-05 |
2011-12-01 |
Amgen Inc. |
FGF21 mutants and uses thereof
|
US8461111B2
(en)
|
2009-05-20 |
2013-06-11 |
Florida State University Research Foundation |
Fibroblast growth factor mutants having improved functional half-life and methods of their use
|
US10241093B2
(en)
|
2009-05-28 |
2019-03-26 |
The Cleveland Clinic Foundation |
Trimethylamine-containing compounds for diagnosis and prediction of disease
|
EP2437775A1
(en)
|
2009-06-04 |
2012-04-11 |
Novartis AG |
Fgf-21 for treating cancers
|
CN102802657A
(zh)
|
2009-06-11 |
2012-11-28 |
诺沃-诺迪斯克有限公司 |
用于治疗2型糖尿病的glp-1和fgf21组合
|
AU2010262927A1
(en)
*
|
2009-06-17 |
2012-01-19 |
Amgen Inc. |
Chimeric FGF19 polypeptides and uses thereof
|
CN101993496B
(zh)
*
|
2009-08-20 |
2013-06-05 |
重庆富进生物医药有限公司 |
双重调节血糖血脂融合蛋白及其制法和用途
|
CN101993485B
(zh)
|
2009-08-20 |
2013-04-17 |
重庆富进生物医药有限公司 |
促胰岛素分泌肽类似物同源二聚体及其用途
|
JP6016636B2
(ja)
|
2009-10-15 |
2016-10-26 |
ジェネンテック, インコーポレイテッド |
改変したレセプター特異性を持つキメラ線維芽細胞増殖因子
|
US8889621B2
(en)
|
2009-10-30 |
2014-11-18 |
New York University |
Inhibiting binding of FGF23 to the binary FGFR-Klotho complex for the treatment of hypophosphatemia
|
UA109888C2
(uk)
|
2009-12-07 |
2015-10-26 |
|
ІЗОЛЬОВАНЕ АНТИТІЛО АБО ЙОГО ФРАГМЕНТ, ЩО ЗВ'ЯЗУЄТЬСЯ З β-КЛОТО, РЕЦЕПТОРАМИ FGF І ЇХНІМИ КОМПЛЕКСАМИ
|
US20110312881A1
(en)
|
2009-12-21 |
2011-12-22 |
Amunix, Inc. |
Bifunctional polypeptide compositions and methods for treatment of metabolic and cardiovascular diseases
|
EP2460527A1
(en)
|
2010-01-21 |
2012-06-06 |
Sanofi |
Pharmaceutical composition for treating a metabolic syndrome
|
US20110195077A1
(en)
|
2010-01-29 |
2011-08-11 |
Novartis Ag |
Methods and compositions using fgf23 fusion ppolypeptides
|
CA2796055A1
(en)
|
2010-04-15 |
2011-10-20 |
Amgen Inc. |
Human fgf receptor and .beta.-klotho binding proteins
|
AU2011239386B2
(en)
|
2010-04-16 |
2015-03-19 |
Salk Institute For Biological Studies |
Methods for treating metabolic disorders using FGF
|
JP2013533227A
(ja)
|
2010-06-08 |
2013-08-22 |
ノヴォ ノルディスク アー/エス |
Fgf21類似体および誘導体
|
US9655974B2
(en)
|
2010-07-20 |
2017-05-23 |
Novo Nordisk A/S |
N-terminal modified FGF21 compounds
|
US20130216608A1
(en)
|
2010-09-09 |
2013-08-22 |
Trifoilium Aps |
Airway Administration of Angiogenesis Inhibitors
|
EP2725034B1
(en)
|
2010-09-22 |
2019-04-03 |
Amgen Inc. |
Carrier immunoglobulins with no specificity for human tissues and uses thereof
|
CN102464712A
(zh)
|
2010-11-11 |
2012-05-23 |
重庆富进生物医药有限公司 |
缺失型人成纤维细胞生长因子21变异体及其偶联物
|
US9023791B2
(en)
|
2010-11-19 |
2015-05-05 |
Novartis Ag |
Fibroblast growth factor 21 mutations
|
JP5613547B2
(ja)
|
2010-12-14 |
2014-10-22 |
株式会社スクウェア・エニックス |
タスクベースの並列プログラミング言語
|
AR084558A1
(es)
|
2010-12-22 |
2013-05-22 |
Marcadia Biotech |
Metodos para tratar trastornos metabolicos y obesidad con peptidos basados en glucagon activos para el receptor de peptido insulinotropico dependiente de glucosa (gip)/peptido-1 similar al glucagon (glp-1)
|
JP5850435B2
(ja)
|
2010-12-24 |
2016-02-03 |
国立研究開発法人産業技術総合研究所 |
ヒトfgf19活性の正確で高感度な測定方法ならびにヒトfgf19活性の制御剤
|
US10752664B2
(en)
|
2011-04-08 |
2020-08-25 |
Amgen Inc. |
Method of treating or ameliorating metabolic disorders using growth differentiation factor 15 (GDF-15)
|
WO2012140650A2
(en)
|
2011-04-12 |
2012-10-18 |
Hepacore Ltd. |
Conjugates of carboxy polysaccharides with fibroblast growth factors and variants thereof
|
MX2013013044A
(es)
|
2011-05-10 |
2014-02-20 |
Amgen Inc |
METODO PARA IDENTIFICAR COMPUESTOS QUE ESPECIFICAMENTE MODULAN LA INTERACCION DE FGFR1 Y ß-KLOTHO.
|
MY175338A
(en)
|
2011-05-16 |
2020-06-19 |
Genentech Inc |
Fgfr1 agonists and methods of use
|
US9574002B2
(en)
|
2011-06-06 |
2017-02-21 |
Amgen Inc. |
Human antigen binding proteins that bind to a complex comprising β-Klotho and an FGF receptor
|
JP2014524735A
(ja)
|
2011-06-08 |
2014-09-25 |
デノボ バイオファーマ (ハンジョウ) リミテッド カンパニー |
レチノイドxレセプターの調節因子の活性を予測する方法および組成物
|
WO2012177481A2
(en)
|
2011-06-24 |
2012-12-27 |
University Of Miami |
Fibroblast growth factor receptor inhibition for the treatment of disease
|
MY163674A
(en)
|
2011-07-01 |
2017-10-13 |
Ngm Biopharmaceuticals Inc |
Compositions, uses and method for treatment of metabolic disorders and diseases
|
EP2548570A1
(en)
|
2011-07-19 |
2013-01-23 |
Sanofi |
Pharmaceutical composition for treating a metabolic syndrome
|
WO2013027191A1
(en)
|
2011-08-25 |
2013-02-28 |
Novartis Ag |
Methods and compositions using fgf23 fusion polypeptides
|
JP2014526441A
(ja)
|
2011-08-31 |
2014-10-06 |
アムジエン・インコーポレーテツド |
1型糖尿病の治療における使用のためのfgf21
|
TWI593708B
(zh)
|
2011-09-26 |
2017-08-01 |
諾華公司 |
治療代謝病症之融合蛋白質
|
TW201315742A
(zh)
|
2011-09-26 |
2013-04-16 |
Novartis Ag |
治療代謝病症之雙功能蛋白質
|
AR087973A1
(es)
|
2011-10-04 |
2014-04-30 |
Lilly Co Eli |
Variantes del factor 21 del crecimiento de fibroblastos
|
CN103127503B
(zh)
|
2011-11-23 |
2017-11-10 |
上海医学生命科学研究中心有限公司 |
拮抗和/或阻断IL‑6/IL‑6R/gp130信号通路在抗肝癌治疗中的用途
|
WO2013109856A2
(en)
|
2012-01-18 |
2013-07-25 |
Genentech, Inc. |
Methods of using fgf19 modulators
|
US9475856B2
(en)
|
2012-03-02 |
2016-10-25 |
New York University |
Chimeric FGF21 proteins with enhanced binding affinity for β-klotho for the treatment of type II diabetes, obesity, and related metabolic disorders
|
JP2013194049A
(ja)
|
2012-03-23 |
2013-09-30 |
Kazuo Todokoro |
ヒト造血幹細胞を増幅させるための組成物及び方法
|
AU2013243951A1
(en)
|
2012-04-02 |
2014-10-30 |
Moderna Therapeutics, Inc. |
Modified polynucleotides for the production of secreted proteins
|
WO2013156920A1
(en)
|
2012-04-16 |
2013-10-24 |
Tel Hashomer Medical Research Infrastructure And Services Ltd. |
Klotho variant polypeptides and uses thereof in therapy
|
US20150141335A1
(en)
|
2012-05-15 |
2015-05-21 |
Eli Lilly And Company |
Therapeutic uses of fibroblast growth factor 21 proteins
|
US9464126B2
(en)
|
2012-06-07 |
2016-10-11 |
New York University |
Chimeric fibroblast growth factor 21 proteins and methods of use
|
US9657075B2
(en)
|
2012-06-07 |
2017-05-23 |
New York University |
Chimeric fibroblast growth factor 23 proteins and methods of use
|
US9474785B2
(en)
|
2012-06-07 |
2016-10-25 |
New York University |
Chimeric fibroblast growth factor 19 proteins and methods of use
|
WO2013188182A1
(en)
|
2012-06-11 |
2013-12-19 |
Eli Lilly And Company |
Fibroblast growth factor 21 variants
|
TWI513705B
(zh)
|
2012-06-11 |
2015-12-21 |
Lilly Co Eli |
纖維母細胞生長因子21蛋白質
|
PT2872491T
(pt)
|
2012-07-11 |
2021-08-05 |
Blueprint Medicines Corp |
Inibidores do recetor do fator de crescimento de fibroblastos
|
TW201420606A
(zh)
|
2012-08-22 |
2014-06-01 |
Lilly Co Eli |
同源二聚體蛋白
|
AU2013311777B2
(en)
|
2012-09-07 |
2018-02-01 |
Sanofi |
Fusion proteins for treating a metabolic syndrome
|
AU2013352363B2
(en)
|
2012-11-28 |
2018-04-12 |
Ngm Biopharmaceuticals, Inc. |
Compositions and methods for treatment of metabolic disorders and diseases
|
US9290557B2
(en)
|
2012-11-28 |
2016-03-22 |
Ngm Biopharmaceuticals, Inc. |
Compositions comprising variants and fusions of FGF19 polypeptides
|
US9273107B2
(en)
|
2012-12-27 |
2016-03-01 |
Ngm Biopharmaceuticals, Inc. |
Uses and methods for modulating bile acid homeostasis and treatment of bile acid disorders and diseases
|
DK2938740T3
(da)
|
2012-12-27 |
2022-06-20 |
Ngm Biopharmaceuticals Inc |
Kimære fgf19-peptider til anvendelse til behandling af galdesyrelidelser
|
US9550820B2
(en)
|
2013-02-22 |
2017-01-24 |
New York University |
Chimeric fibroblast growth factor 23/fibroblast growth factor 19 proteins and methods of use
|
WO2014152090A1
(en)
|
2013-03-14 |
2014-09-25 |
Georgetown University |
Compositions and treatments of metabolic disorders using fgf binding protein 3 and fgf 19
|
WO2014152089A1
(en)
|
2013-03-14 |
2014-09-25 |
Georgetown University |
Compositions and treatments of metabolic disorders using fgf binding protein 3
|
US9789160B2
(en)
|
2013-03-14 |
2017-10-17 |
Georgetown University |
Treatments for lowering glucose levels using FGF binding protein 3
|
WO2014149699A1
(en)
|
2013-03-15 |
2014-09-25 |
Eli Lilly And Company |
Bifunctional protein
|
US9835631B2
(en)
|
2013-04-15 |
2017-12-05 |
Nordic Bioscience A/S |
Combined biomarker measurement of fibrosis
|
MX2016005101A
(es)
|
2013-10-21 |
2017-01-09 |
Salk Inst For Biological Studi |
Factor de crecimiento de fibroblastos (fgf) 1 mutado y procedimientos de uso.
|
SG11201602870YA
(en)
|
2013-10-28 |
2016-05-30 |
Ngm Biopharmaceuticals Inc |
Cancer models and associated methods
|
UA119863C2
(uk)
|
2014-01-24 |
2019-08-27 |
Нгм Біофармасьютікалс, Інк. |
Антитіло або його фрагмент, що зв'язується з бета-клото
|
US20170173114A1
(en)
|
2014-05-07 |
2017-06-22 |
Joslin Diabetes Center, Inc. |
Methods and compositions for induction of ucp1 expression
|
WO2015183890A2
(en)
|
2014-05-28 |
2015-12-03 |
Ngm Biopharmaceuticals, Inc. |
Methods and compositions for the treatment of metabolic disorders and diseases
|
AU2015277438B2
(en)
|
2014-06-16 |
2020-02-27 |
Ngm Biopharmaceuticals, Inc. |
Methods and uses for modulating bile acid homeostasis and treatment of bile acid disorders and diseases
|
WO2016048995A2
(en)
|
2014-09-23 |
2016-03-31 |
Salk Institute For Biological Studies |
Fgf19 truncations and mutants and uses thereof
|
CN107108711B
(zh)
|
2014-10-23 |
2021-11-23 |
恩格姆生物制药公司 |
包含肽变异体的药物组合物及其使用方法
|
US10434144B2
(en)
|
2014-11-07 |
2019-10-08 |
Ngm Biopharmaceuticals, Inc. |
Methods for treatment of bile acid-related disorders and prediction of clinical sensitivity to treatment of bile acid-related disorders
|
EP3108893A1
(en)
|
2015-06-25 |
2016-12-28 |
Universite Claude Bernard - Lyon 1 |
Novel therapeutic use of fgf19
|
WO2017053842A1
(en)
|
2015-09-24 |
2017-03-30 |
Genentech, Inc. |
Methods for the treatment of epilepsy
|
JP6728352B2
(ja)
|
2015-11-09 |
2020-07-22 |
エヌジーエム バイオファーマシューティカルス,インコーポレーテッド |
胆汁酸に関係した障害の治療方法
|
AU2017315459B2
(en)
|
2016-08-26 |
2023-06-29 |
Ngm Biopharmaceuticals, Inc. |
Methods of treating fibroblast growth factor 19-mediated cancers and tumors
|
CA3034435A1
(en)
|
2016-08-29 |
2018-03-08 |
Lei Ling |
Methods for treatment of bile acid-related disorders
|
KR102340750B1
(ko)
|
2017-03-03 |
2021-12-21 |
에이치엘비테라퓨틱스 주식회사 |
티모신 베타 4를 유효성분으로 포함하는 안정화된 외용 제제
|
CN108619490A
(zh)
|
2017-03-22 |
2018-10-09 |
天士力医药集团股份有限公司 |
一种长效化突变的人源成纤维生长因子的新用途
|
WO2018195390A1
(en)
|
2017-04-21 |
2018-10-25 |
Ngm Biopharmaceuticals, Inc. |
Methods of treating gastrointestinal motility -related disorders using variants and fusions of fgf19/fgf21 polypeptides
|
CN110997726A
(zh)
|
2017-07-06 |
2020-04-10 |
耶鲁大学 |
治疗或预防内分泌fgf-关联疾病的组合物和方法
|
WO2020176703A1
(en)
|
2019-02-28 |
2020-09-03 |
Ngm Biopharmaceuticals, Inc. |
Non-invasive biomarkers for use in the treatment of non-alcoholic steatohepatitis and other bile acid-related disorders
|
EP3955954A4
(en)
|
2019-04-17 |
2023-05-17 |
NGM Biopharmaceuticals, Inc. |
MULTIPLE THERAPY FOR THE MODULATION OF BILE ACID HOMEOSTASIS AND THE TREATMENT OF BILE ACID DISORDERS AND DISEASES
|